Who are Aspirin loading dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Plavix, Aspirin, ASA, Dabigatran + clopidogrel, Clopidogrel reloading, Clopidogrel active metabolite.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aspirin-loading-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Aspirin loading dose — Competitive Intelligence Brief

Aspirin loading dose (Aspirin loading dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent; nonsteroidal anti-inflammatory drug (NSAID). Area: Cardiovascular.

marketed Antiplatelet agent; nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Aspirin loading dose (Aspirin loading dose) — Icahn School of Medicine at Mount Sinai. Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes to reduce thromboxane A2 production and platelet aggregation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aspirin loading dose TARGET	Aspirin loading dose	Icahn School of Medicine at Mount Sinai	marketed	Antiplatelet agent; nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Plavix	clopidogrel	Generic (originally Sanofi/BMS)	marketed	Thienopyridine antiplatelet agent	Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter	1997-11-17
Aspirin	acetylsalicylic acid	Bayer AG	marketed	NSAID, Antiplatelet agent	Gamma-glutamyltranspeptidase 1, Nicotinate phosphoribosyltransferase, Acid-sensing ion channel 3	1899-03-06
ASA	ASA	Biogen	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Dabigatran + clopidogrel	Dabigatran + clopidogrel	Zuyderland Medisch Centrum	marketed	Anticoagulant + antiplatelet agent combination	Thrombin (Factor IIa) and P2Y12 receptor
Clopidogrel reloading	Clopidogrel reloading	University of Pecs	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
Clopidogrel active metabolite	Clopidogrel active metabolite	University of Florida	marketed	P2Y12 receptor antagonist / Antiplatelet agent	P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent; nonsteroidal anti-inflammatory drug (NSAID) class)

Icahn School of Medicine at Mount Sinai · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aspirin loading dose — Competitive Intelligence Brief. https://druglandscape.com/ci/aspirin-loading-dose. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab